The
costliness of Priligy, a medication primarily prescribed for premature ejaculation, stems from various factors inherent in its development, production, and distribution processes. Firstly, pharmaceutical companies invest significant resources in research and development to bring novel medications like Priligy to market, which often entails substantial financial outlays for clinical trials, regulatory approvals, and patent protections. Additionally, the complexity of its manufacturing process, coupled with stringent quality control measures, contributes to production expenses. Furthermore, the relatively limited market demand compared to more widely prescribed medications may lead to higher unit costs to recoup investments and maintain profitability. Moreover, factors such as insurance coverage limitations, patent exclusivity, and lack of generic alternatives can further elevate the price of Priligy for consumers.
